Secondly, the molecular mechanisms of PLCG2 in CRC and TME, especially the modulation of immune checkpoints and CD8+ T cells, require in-depth explorations to clarify the crucial role of PLCG2 and to discover more therapeutic targets, which is also the focus of our subsequent research. The gene discussed is PLCG2; the disease is colorectal carcinoma.